SGP’s HCV franchise is generating sales at a $1.3B annual rate despite its consisting of: 1. A second-best product in its class (Peg-Intron); 2. An obsolete product (Intron-A); and 3. A product whose patent has run out (Rebetol). They must have some good sales reps.